Items where Author is "Joerger, M."
Number of items: 12. 2014Joerger, M. and Schaer-Thuer, C. and Koeberle, D. and Matter-Walstra, K. and Gibbons-Marsico, J. and Diem, S. and Thuerlimann, B. and Cerny, T.. (2014) Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. European Journal of Clinical Pharmacology, 70 (6). p. 719. 2013Mueller, F. and Büchel, B. and Köberle, D. and Schürch, S. and Pfister, B. and Krähenbühl, St and Froehlich, T. K. and Largiader, C. R. and Joerger, M.. (2013) Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer chemotherapy and pharmacology, Vol. 71, H. 2. pp. 361-370. Joerger, M. and Thürlimann, B. and Savidan, A. and Frick, H. and Rageth, C. and Lütolf, U. and Vlastos, G. and Bouchardy, C. and Konzelmann, I. and Bordoni, A. Probst-Hensch and Jundt, G. and Ess, S.. (2013) Treatment of breast cancer in the elderly : a prospective, population-based Swiss study. Journal of geriatric oncology, Vol. 4, H. 1. pp. 39-47. 2012Joerger, M. and Thürlimann, B. and Savidan, A. and Frick, H. and Bouchardy, C. and Konzelmann, I. and Probst-Hensch, N. and Ess, S.. (2012) A population-based study on the implementation of treatment recommendations for chemotherapy in early breast cancer. Clinical breast cancer, Vol. 12, H. 2. pp. 102-109. Joerger, M. and Ferreri, A. J. M. and Krähenbühl, S. and Schellens, J. H. M. and Cerny, Th and Zucca, E. and Huitema, A. D. R.. (2012) Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. British journal of clinical pharmacology, Vol. 73, H. 2. pp. 240-247. 2011Joerger, M. and Matter-Walstra, K. and Früh, M. and Kühnel, U. and Szucs, T. and Pestalozzi, B. and Schwenkglenks, M.. (2011) Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer : a cost-utility analysis. Annals of Oncology, Vol. 22, H. 3. pp. 567-574. Joerger, M. and Riesen, W. F. and Thürlimann, B.. (2011) Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer. Journal of oncology pharmacy practice, Vol. 17, H. 3. pp. 292-294. Ess, S. and Joerger, M. and Frick, H. and Probst-Hensch, N. and Vlastos, G. and Rageth, C. and Lütolf, U. and Savidan, A. and Thürlimann, B.. (2011) Predictors of state-of-the-art management of early breast cancer in Switzerland. Annals of Oncology, Vol. 22, H. 3. pp. 618-624. Joerger, M. and Templeton, A. and Köberle, D. and Engler, H. and Riesen, W. F. and Thürlimann, B.. (2011) Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. Cancer chemotherapy and pharmacology, Vol. 67, H. 5. pp. 1137-1144. Joerger, M. and Thürlimann, B. and Huober, J.. (2011) Small HER2-positive, node-negative breast cancer : who should receive systemic adjuvant treatment? Annals of oncology, Vol. 22. pp. 17-23. 2010Joerger, M. and Huitema, A. D. R. and Krähenbühl, S. and Schellens, J. H. M. and Cerny, T. and Reni, M. and Zucca, E. and Cavalli, F. and Ferreri, A. J. M.. (2010) Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma : a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. British journal of cancer, Vol. 102, H. 4. pp. 673-677. 2008Joerger, M. and Nuessli, D. F. and Henz, S. and Zaunbauer, W. and Cerny, T. and Cogliatti, S. B. and Gillessen, S.. (2008) CT-diagnosed mesenteric alterations in patients with non-Hodgkin's lymphoma: a population-based study. Onkologie, 31 (10). pp. 514-519. |
